Relma-Cel Continues to Elicit Responses in Chinese Patients

Relmacabtagene autoleucel continued to induce responses with acceptable tolerability in Chinese patients with relapsed or refractory mantle cell lymphoma.

Related Keywords

Beijing , China , Peking , Yuqin , Xizang , Chinese , , Mantle Cell Lymphoma International Prognostic Index , Key Laboratory Of Carcinogenesis , Department Of Lymphoma , Key Laboratory , Translational Research , Peking University Cancer Hospital , Cell Lymphoma International Prognostic Index , Relmacabtagene Autoleucel , Relma Cel , Elicit Responses , Mantle Cell Lymphoma , Phase 2 Study Nct04718883 ,